Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Cuprizone neurotoxicity in the rat: morphologic observations.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Breastfeeding is not related to postpartum relapses in multiple sclerosis.
The value of qualitative and quantitative assessment of lesion to cerebral cortex signal ratio on double inversion recovery sequence in the differentiation of demyelinating plaques from non-specific T2 hyperintensities.
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
“Human Medicines” page
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Rituximab does not reset defective early B cell tolerance checkpoints.

Pages